SEC investigates Cyberonics
This article was originally published in The Gray Sheet
Executive Summary
Stock options granted by the company on June 15, 2004 are under inquiry by the Securities & Exchange Commission, according to a June 9 8-K filing. The options were offered the same day FDA's Neurological Devices Panel voted in favor of approving Cyberonics' treatment-resistant-depression device, VNS Therapy, while shares were halted for external trading (1"The Gray Sheet" June 21, 2004, p. 3). The firm's issue leapt 78% to $34.81 from June 14, 2004 to June 16, 2004, the day after the panel decision. Cyberonics claims that the grants were approved by the board of directors without any management influence...
You may also be interested in...
Cyberonics stock option query widens
On the heels of a recently initiated "informal" Securities & Exchange Commission inquiry into the firm's issuance of stock options in June 2004, Cyberonics receives a subpoena June 26 from the U.S. Attorney's Office for the Southern District of New York on the same issue. The options were offered to executives on the same day that the firm's VNS Therapy device for depression went before FDA's Neurological Devices Panel. Trading for outside investors had been suspended during the panel review. Cyberonics claims that the grants were approved by the board of directors without management influence (1"The Gray Sheet" June 19, 2006, In Brief)...
Cyberonics Advertisement Brought To FDA’s Attention By Public Citizen
FDA's Office of Device Evaluation is looking into a consumer-directed advertisement for Cyberonics' VNS Therapy device for treatment-resistant depression
Cyberonics’ VNS Therapy Approvable As Last-Resort Depression Fix – Panel
FDA's Neurological Devices Panel set aside its desire for an additional, randomized trial of Cyberonics' VNS Therapy depression indication at a June 15 meeting to review the device in Gaithersburg, Md